Targeted therapy in biliary tract cancers-current limitations and potentials in the future

Area of Science:

• Oncology
• Gastroenterology
• Molecular Biology

Background:

• Biliary tract cancers (BTC), encompassing cholangiocarcinoma (CCA), intrahepatic (iCCA), extrahepatic (eCCA), and gallbladder carcinoma (GBC), represent aggressive epithelial malignancies.
• These cancers exhibit significant heterogeneity in etiology, epidemiology, and molecular profiles, leading to limited treatment options and poor survival rates, especially in advanced or metastatic stages.
• Current systemic treatment relies on gemcitabine and cisplatin chemotherapy, with a lack of identifiable, actionable molecular targets hindering the development of targeted therapies.

Purpose of the Study:

• To highlight the heterogeneity and challenges in treating biliary tract cancers (BTC).
• To emphasize the need for a deeper understanding of BTC carcinogenesis, tumor-stroma interactions, and molecular pathways.
• To advocate for the development of targeted, individualized therapies to improve patient survival and outcomes.

Main Methods:

• Review of current understanding of biliary tract cancer (BTC) biology and treatment landscape.
• Analysis of the heterogeneity in etiology, epidemiology, and molecular profiles of BTC.
• Identification of knowledge gaps in BTC carcinogenesis and therapeutic strategies.

Main Results:

• Biliary tract cancers (BTC) are a heterogeneous group of malignancies with limited effective treatment options.
• The lack of a common genetic signature impedes the identification of actionable targets for therapy.
• Current targeted agents have shown limited clinical benefit, underscoring the need for novel approaches.

Conclusions:

• A comprehensive understanding of BTC carcinogenesis, tumor-stroma interactions, and key molecular pathways is essential.
• Developing targeted and individualized therapies is crucial for overcoming the heterogeneity of BTC.
• Improving survival and overall patient outcomes requires a shift towards personalized treatment strategies for biliary tract cancers.